Further experience with chemotherapy in the Dunning prostatic adenocarcinoma.
A number of chemotherapeutic agents, including L-asparaginase, actinomycin D, chloroethylcyclohexy-nitrosourea, 5-flourouracil, cyclophosphamide, hydroxyurea, cis-platinum, adriamycin and methotrexate, alone and in combination and at variable dose levels, were applied against the Dunning R3327 rat prostatic adenocarcinoma-subline G. We found a continuing parallel between responses of the human and rat tumors and conclude that the usefulness of this animal model as a screening system for agents against the human tumor is further supported.
D000230:Adenocarcinoma / Q000188:drug therapy*; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use* / Q000633:toxicity; D001215:Asparaginase / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D003609:Dactinomycin / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005472:Fluorouracil / Q000627:therapeutic use; D006824:Hybridization, Genetic; D006918:Hydroxyurea / Q000627:therapeutic use; D008130:Lomustine / Q000627:therapeutic use; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D009374:Neoplasms, Experimental / Q000188:drug therapy; D010984:Platinum / Q000627:therapeutic use; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D051381:Rats
D000970:Antineoplastic Agents; D003609:Dactinomycin; D010984:Platinum; D008130:Lomustine; D004317:Doxorubicin; D003520:Cyclophosphamide; D001215:Asparaginase; D005472:Fluorouracil; D006918:Hydroxyurea; D008727:Methotrexate